Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$53.00 USD
+0.87 (1.67%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $53.35 +0.35 (0.66%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Price, Consensus and EPS Surprise
HALO 53.00 +0.87(1.67%)
Will HALO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HALO
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Other News for HALO
Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Company (TAK), Amgen (AMGN) and Halozyme (HALO)
TD Cowen Remains a Buy on Halozyme (HALO)
Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside
Halozyme Therapeutics shares fall as Wells Fargo cuts rating to equal weight
Halozyme just downgraded at Wells Fargo, here's why